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ABSTRACT
Human sirtuin 1 (SIRT1) is a NAD
+-dependent
deacetylase that participates in cell death/survival,
senescence and metabolism. Although its
substrates are well characterized, no direct
regulators have been defined. Here, we show that
SIRT1 associates with SKI-interacting protein
(SKIP) and modulates its activity as a coactivator
of retinoic acid receptor (RAR). Binding assays
indicated that SKIP interacts with RAR in a RA-
dependent manner, through a region that overlaps
the binding site for SIRT1. SKIP augmented
the transcriptional activation activity of RAR by
cooperating with SRC-1, and SIRT1 suppressed
SKIP/SRC-1-enhanced RAR transactivation
activity. The suppression was dependent on the
deacetylase activity of SIRT1 and was enhanced
by a SIRT1 activator, resveratrol. In contrast, the
suppression was relieved by SIRT1 knockdown,
overexpression of SKIP and treatment with a
SIRT1 inhibitor, splitomicin. Upon SKIP over-
expression, the recruitment of SIRT1 to the
endogenous RARb2 promoter was severely
impaired, and SKIP was recruited to the promoter
instead. Finally, resveratrol treatment inhibited
RA-induced neuronal differentiation of P19 cells,
accompanied by reductions in the neuronal marker
nestin and a RAR target gene, RARb2. This inhibition
was relieved by either knockdown of SIRT1 or
overexpression of SKIP. These data suggest that
SIRT1 and SKIP play reciprocal roles in the
regulation of RAR activity, which is implicated in
the regulation of RA-induced neuronal differentia-
tion of P19 cells.
INTRODUCTION
Human SIRT1 (sirtuin1), one of the seven mammalian
SIRT homologs, is closely related to yeast Sir2, which
possesses NAD
+-dependent class III histone deacetylase
activity. Recent studies strongly suggest that mammalian
SIRT1, like yeast Sir2, is involved in transcriptional
silencing of integrated reporter genes by chromatin mod-
iﬁcation via histone deacetylation, DNA damage
responses (1,2),and life span extension following caloric
restriction (3). SIRTI also deacetylates non-histone
proteins, including various transcription factors that are
involved in growth regulation, the stress response and
endocrine signaling. For example, SIRT1 negatively
regulates p53-dependent apoptosis by deacetylating p53
in response to cellular damage (4–6). Other substrates of
SIRT1, including DNA repair protein Ku70 (7), FOXO
family proteins (8–9) and NF-kB (10), are involved in the
stress response. In energy metabolism and insulin signal-
ing, SIRT1 activates gluconeogenesis and represses
glycolysis in the liver via deacetylation of PGC-1a (11).
Increasing levels of SIRT1 in the pancreatic b cells of mice
resulted in repressed UCP2 transcription and enhanced
glucose-stimulated insulin secretion (12). Upon binding,
SIRT1 deacetylates the androgen receptor (AR) and
represses DHT-induced AR signaling in human prostate
cancer (13). Thus, it has been speculated that SIRT1 is
widely involved in mammalian physiology, with roles in
metabolism, senescence, apoptosis and tumorigenesis.
In addition, recent studies have suggested a role for
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receptor PPARg by docking with its co-repressors, NcoR
and SMRT, and attenuates adipogenesis in 3T3-L1 cells
(14). SIRT1 also regulates muscle gene expression and dif-
ferentiation by deacetylating MyoD and PCAF (15).
Moreover, SIRT1 participates in the growth and mat-
uration of the embryo and in gametogenesis (16).
Nevertheless, a role of SIRT1 in neuronal diﬀerentiation,
specially derived from embryonic stem cells, remains
largely unknown.
To identify additional targets of SIRT1, we ﬁrst
performed a yeast two-hybrid screen of a human comple-
mentary DNA (cDNA) library using SIRT1 as bait, and
found that SIRT1 is functionally associated with SKI-
interacting protein (SKIP), which has been described as
a transcriptional coactivator of nuclear receptors and
other transcription regulators (17,18). Here, we provide
the ﬁrst evidence for a retinoic acid receptor (RAR)
regulatory pathway controlled reciprocally by SIRT1
and SKIP.
MATERIALS AND METHODS
Plasmids and cloning
All cDNAs were made according to standard methods and
veriﬁed by sequencing. The full-length SKIP cDNA was
ampliﬁed by PCR from a HeLa cDNA library and was
inserted into the 50-XhoI and 30-BamHI or 30-BglII sites of
each vector. Expression plasmids for the SIRT1 wild type
and point mutant (SIRT1 HY) are described elsewhere
(19). For yeast two-hybrid screening, the full-length
SIRT1 cDNA was inserted into the bait plasmid
pBTM116 (LexA DBD vector). SIRT1 deletion mutants
were created by PCR ampliﬁcation and were also
subcloned into pBTM116. For transient transfections,
the Flag-tagged SIRT1 or SKIP gene was placed in the
pcDNA3 vector. For the localization assay, GFP-tagged
recombinant constructs were created in pEGFP-C3 (BD
Biosciences, Palo Alto, CA, USA), respectively. For GST-
fused proteins, pGEX4T-1 (Amersham Pharmacia
Biotech, Piscataway, NJ, USA) was used.
Cell culture and diﬀerentiation
The H1299 cells derived from a non-small-cell lung tumor
were grown and maintained in RPMI 1640 medium, and
COS-1, P19, and HEK293 cells were grown and main-
tained in Dulbecco’s Modiﬁed Eagle Medium (DMEM)
medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS) and an antibiotic-antimycotic mix
(all from Gibco BRL, Gaithersburg, MD, USA) in
a5 %C O 2 atmosphere at 37 C. For diﬀerentiation,
P19 cells were aggregated in bacterial Petri plates at a
density of 10
5cells/ml and treated with 1mM RA and/or
120mM resveratrol (RES) for 96h, with subculturing in
fresh medium after 48h with each treatment. On day 4,
the aggregates were transferred to cell culture plates, and
RA was eliminated from the medium. Cells were then
seeded on 10-cm-diameter plates, at a density of 3 10
5
cells/plate. After 12h, the medium was changed to 0.5%
FBS medium, and the cells were allowed to diﬀerentiate
for another 6 days.
Yeast two-hybrid screening and assay
A HeLa cDNA library in the prey plasmid pGAD10 (BD
Biosciences) was screened for proteins that interacted with
SIRT1, using the yeast reporter strain L40. Screening was
performed as reported previously, using LexA-fused
SIRT1 as the bait (19). To map the SKIP interaction
domain of SIRT1, deletion derivatives of SIRT1 were
fused with LexA DBD by subcloning into pBTM116.
The deletion mutants of SKIP were fused with VP16
AD by subcloning into the pASV3 vector. The level
of interaction was determined by quantitative
b-galactosidase assays.
GST pull-down assay
A GST-fusion protein of SKIP (amino acids 174–373) or
SIRT1 (amino acids 114–217) was expressed in
Escherichia coli and puriﬁed on glutathione-Sepharose
beads (Amersham Pharmacia Biotech) by standard
methods. An approximately equal amount of GST or
GST-SIRT1 was mixed with in vitro translated Flag-
SIRT1, SKIP or RARa using a TNT reticulocyte system
(Promega, Madison, WI, USA). Bound proteins were
detected on western blots with antibodies against Flag
(for SIRT1 and SKIP) and RARa.
Western blotting, immunoprecipitation and
immunoﬂuorescence microscopy
For western blotting (WB), cells were lysed in lysis buﬀer
(20) supplemented with a protease inhibitor cocktail
(Roche, Basel, Switzerland). Proteins were separated by
electrophoresis on 8–12% sodium dodecyl sulfate (SDS)-
polyacrylamide gels, transferred to nitrocellulose, and
incubated with primary antibodies. The commercially
available primary antibodies used were rabbit polyclonal
antibodies (SIRT1, sc-15404; RARa, sc-551; RARb,
sc-552; GFP, sc-8334: Santa Cruz Biotechnology, Santa
Cruz, CA, USA), mouse monoclonal anti-Flag M2
antibody (F3165; Sigma, St Louis, MO, USA) and
mouse monoclonal anti-b-actin antibody (A1978;
Sigma). The blots were next incubated with peroxidase-
conjugated mouse or rabbit IgG secondary antibodies
(Amersham Pharmacia Biotech). The protein bands were
detected with an ECL system (Amersham Pharmacia
Biotech).
For the immunoprecipitation (IP) assay, cells treated
under various conditions were washed with ice-cold
phosphate-buﬀered saline (PBS) and lysed in RIPA
buﬀer supplemented with a protease inhibitor cocktail
(Roche) (20). The lysates were incubated overnight at
4 C with a 1:200 dilution of the indicated antibodies.
After 2h of incubation at 4 C with A/G-agarose beads
(Santa Cruz Biotechnology), the beads were washed
three times with RIPA buﬀer. The immune complexes
were released from the beads by boiling and analyzed by
WB using the indicated antibodies.
For co-localization, H1299 cells were co-transfected
with GFP-SKIP and Flag-SIRT1 or Flag-RARa, washed
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1min at room temperature, and then permeabilized for
4min in PBS containing 0.5% Triton X-100. After
washing, the cells were incubated with anti-SIRT1 or
anti-RARa antibody (1:100 dilution) in blocking buﬀer
(PBS and 2% BSA) for 1h and then incubated with Texas
Red-conjugated anti-rabbit IgG (1:200 dilution;
Amersham Pharmacia Biotech). After the ﬁnal washing,
the cells (either GFP- or Texas Red-labeled) were
visualized under a ﬂuorescence microscope (AX70;
Olympus Optical Co, Tokyo, Japan). Hoechst (Sigma)
staining was used to localize chromosomal DNA in the
nucleus.
Transient transfection and luciferase reporter assay
HEK293 cells were seeded in a 12-well culture plate and
transiently transfected with RARE-luciferase reporter
enzyme, and SV40-driven b-galactosidase (b-gal) expres-
sion vector as an internal control. Depending on the
experimental conditions, the SIRT1, SIRT1 HY or
SKIP expression vector was co-transfected using
Lipofectamine Plus reagent (Invitrogen). The luciferase
activity was measured by adding 20ml of luciferin into
30ml of cell lysate and using an analytical luminescence
luminometer, according to the manufacturer’s instructions
(Promega). The b-gal activity was determined in 96-well
plates using a microplate reader at 405nm. The luciferase
activity was normalized to the b-gal activity.
Real-time-reverse transcriptase
Total RNA from undiﬀerentiated or diﬀerentiated P19
cells was extracted using TRIzol reagent (Gibco-BRL)
according to the manufacturer’s instructions. RNA
(5mg) was reverse-transcribed using Superscript II
reverse transcriptase (RT; Invitrogen) and oligo(dT)
primer (New England Biolabs, Beverly, MA, USA). The
primers used for PCR were as follows: nestin, forward,
50-CAGATGTGGGAGCTCAATCG-30, and reverse,
50-GCCTCCTCGATGGTCCGCTC-30; glyceraldehydes-
3-phosphate dehydrogenase (GAPDH), forward, 50-GTG
GATATTGTTGCCATCA-30 and reverse, 50-GACTCCA
CGACGTACTCA-30; Hoxa1, forward, 50-TGGAGGAA
GTGAGAAAGTTGG C-30, and reverse, 50-ATGGGAG
TCGAGAGGTTTCC-30; Hoxb1, forward, 50-CCATATC
CTCCGCCGCAG-30, and reverse, 50-CGGACTGGTCA
GAGGCATC-30.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) analysis was
performed as described previously (20). H1299 cells were
transfected with empty Flag vector or Flag-SKIP vector
and treated with or without 1mM AtRA for 4h. Cross-
linked, immunoprecipitated chromatin complexes were
obtained by IP with the indicated antibodies, and the
cross-linking was reversed according to Upstate’s
protocol (Upstate, Chicago, IL, USA). The DNA pellets
were recovered and analyzed by PCR, using a primer pair
that encompasses the RAR2 promoter region: forward,
50-AAGCTCTGTGAGAATCCTG-30, and reverse, 50-G
GATCCTACCCCGACGGTG-30.
RNA interference
The sequences of the custom siRNA duplex for SIRT1
and the control have been described (19). The transfection
of siRNA was performed with Lipofectamine 2000 (Gibco
BRL) in Opti-MEM I reduced-serum medium (Gibco
BRL), according to the manufacturer’s instructions.
SIRT1 knockdown was veriﬁed by WB using anti-
SIRT1 antibody.
RESULTS
SIRT1 interacts speciﬁcally with SKIP through
distinct domains
To identify cellular regulator(s) of SIRT1, we performed a
yeast two-hybrid genetic screening of a HeLa cDNA
library fused to GAL4 AD (activation domain), with
LexA-fused SIRT1 as bait. We identiﬁed a SKIP/NCoA-
62 protein from several rounds of screening and selection.
SKIP, a transcriptional co-regulator, modulates the
transcriptional activities of various transcription factors,
including nuclear receptors such as vitamin D receptor
(VDR) (17,18). The structural features of SIRT1 and
SKIP are depicted in Figure 1A. Yeast two-hybrid
assays using LexA DBD-fused SIRT family members
and Gal4 AD-fused SKIP constructs revealed that, of
the seven SIRT members, SKIP selectively associates
with SIRT1 (Figure 1B). Further domain-mapping
assays indicated that amino acid residues 174–373 of
SKIP (Figure 1C) and 114–217 of SIRT1 (Figure 1D)
are responsible for the interaction between SKIP and
SIRT1. Amino acid residues 114–217 of SIRT1 are
distinct from other SIRT family members, supporting a
speciﬁc interaction of SKIP with SIRT1 among the SIRT
family.
SIRT1 interacts with SKIP in vitro and in vivo
Using a GST pull-down assay, we determined that SIRT1
directly interacts with amino acids 174–373 of SKIP
in vitro (Figure 2A). The physical interaction of SIRT1
and SKIP in mammalian cells was conﬁrmed by perform-
ing IP assays. Flag-tagged SIRT1 was co-transfected
along with an empty GFP or GFP-tagged SKIP construct
in COS-1 cells. IP with an anti-GFP antibody and WB
with an anti-Flag antibody indicated that SIRT1
interacted with SKIP in vivo (Figure 2B, left). This result
was veriﬁed by reverse co-transfection, followed by IP
with an anti-Flag antibody and WB with an anti-GFP
antibody (Figure 2B, right). To further substantiate our
proposed mode of interaction, we determined the
subcellular distribution of SIRT1 and SKIP in H1299
cells. Immunoﬂuorescence microscopy showed that Flag-
SIRT1 and GFP-SKIP were co-localized in speckle-like
nuclear substructures (Figure 2C).
SKIP interacts with RARa through an overlapping
binding domain for SIRT1
SKIP was originally discovered as a nuclear protein that
interacts with the SKI oncoprotein (21), and was later
found to interact with VDR, augmenting VDR-activated
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other nuclear receptor-mediated transcriptional
activations, we ﬁrst investigated whether SKIP could
interact with other nuclear receptors and the ligand-
dependency requirement for the interaction. As shown
by the yeast two-hybrid assays, SKIP interacts with
RARa and ERa in a ligand-dependent manner, whereas
no ligand dependency was observed for the interaction
between SKIP and VDR, and no interactions were
detected between SKIP and TRa or RXRa (Figure 3A).
We selected RARa for further studies because of its
ligand-dependent interaction with SKIP. Subsequent
domain-mapping assays using a series of N- and
C-terminal deletions of SKIP indicated that RARa can
bind to the central region of SKIP, covering amino acids
174–373, which overlaps with the SIRT1 binding region
(Figure 3B). This observation was further conﬁrmed by
immunoﬂuorescence microscopy. When GFP-SKIP and
Flag-RARa were co-expressed in the absence of RA,
SKIP displayed speckle-like nuclear substructures, as
shown in Figure 3C, while RARa localized in the
nucleoplasm. However, RA treatment caused the two
proteins to merge in the nucleoplasm, supporting an
RA-dependent interaction between RARa and SKIP.
SKIP competes with SIRT1 for RARa binding
Given that SKIP can interact with both SIRT1 and RA-
bound RARa, we probed whether SIRT1 interacts with
RARa in the presence of RA. IP and subsequent WB
assays using Flag-SKIP overexpression cellular extracts
indicated that RARa forms a complex with both SKIP
and SIRT1. Complex formation with SKIP was RA
dependent, and complex formation with SIRT1 was RA
enhanced (Figure 4A). The RA-enhanced interaction of
SIRT1 with RARa was conﬁrmed with a GST pull-
down assay using puriﬁed GST-SIRT1 (amino acids
114–217) and in vitro translated RARa (Figure 4B). This
portion of SIRT1 is also responsible for SKIP binding, as
described in Figure 1D, suggesting that SKIP and SIRT1
compete with each other for RA-dependent interactions
with RARa. To analyze the competition between SIRT1
and SKIP for RARa binding in vivo, H1299 cells were
transfected with increasing amounts of Flag-tagged
SKIP expression vector. Cellular extracts were then sub-
jected to IP with anti-RARa antibody and WB with anti-
Flag (for SKIP) and anti-SIRT1 antibody. The SIRT1
binding to RARa decreased inversely with SKIP expres-
sion (Figure 4C). Similarly, the GST pull-down assays
revealed that RARa binding to GST-SIRT1 decreased
Figure 1. Mapping of the interaction domains between SKIP and SIRT1. (A) Structural features of SKIP and SIRT1. (B) Speciﬁc interaction of
SKIP with SIRT1 among the SIRT family. Yeast two-hybrid assays were performed using LexA DBD-fused SIRT family members (SIRT 1–7) and
Gal4 AD-fused SKIP (originally recovered from a yeast two-hybrid screening). The interaction was evaluated by b-gal assays. Fold-activity indicates
the value relative to the value of the Gal4 AD empty control. (C) Mapping of the SKIP domain responsible for SIRT1 binding. SKIP deletions were
fused to the Gal4 AD vector and introduced into yeast L40, together with LexA DBD-fused SIRT1. Fold-activity indicates the b-gal value relative to
that of the VP16 AD-SKIP plus LexA DBD empty control. (D) Mapping of the SIRT1 domain responsible for SKIP binding. SIRT1 deletions were
fused to the LexA DBD vector and introduced into yeast L40, together with Gal4 AD-fused SKIP. Fold-activity indicates the b-gal value relative to
that of the LexA DBD-SIRT1 plus Gal4 AD empty control. All the results are the means of three independent experiments±SD.
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Overall, our in vivo and in vitro assays revealed that
SKIP forms a complex with SIRT1 and RARa at its
low level but compete with SIRT1 for RARa binding at
high level, suggesting that SKIP and SIRT1 may play
reciprocal roles in regulating RARa activity.
SKIP enhances and SIRT1 represses the transcriptional
activity of RARa
To evaluate whether the RARa binding observed above is
functionally relevant, we determined the eﬀects of SIRT1
or SKIP on the transcriptional activity of RARa, using
the RA-responsive RARE-luciferase reporter gene. As
shown in Figure 5A, SKIP enhanced and SIRT1 repressed
the RA-dependent transcriptional activation of RARa in
a dose-dependent manner. Further assays using a
deacetylase-defective SIRT1 mutant (HY) demonstrated
that the deacetylase activity of SIRT1 is required for
RARa repression (Figure 5B). When SIRT1 was
depleted by siRNA treatment, RARa activity increased
markedly, supporting that SIRT1 itself mediates RARa
repression (Figure 5C). As expected from another report
(23), SKIP and a steroid receptor coactivator, SRC-1,
cooperated for RA-induced RARa transcriptional activa-
tion, but this cooperation was again diminished by SIRT1
in a deacetylase activity-dependent manner (Figure 5D).
To conﬁrm the deacetylase activity-dependent RARa
repression mediated by SIRT1, a known SIRT1 inhibitor,
splitomicin (Splito) and an activator, RES, were utilized.
RARa repression by SIRT1 was impaired completely by
splitomicin. However, RARa repression was achieved by
RES without SIRT1 over-expression, and this repression
was released by SKIP over-expression (Figure 5E). We
next investigated whether this competition for RARa
binding occurs in vivo, by ChIP assays. Under normal
conditions, SIRT1 was recruited to the chromatinized
RAR2 promoter in the presence of RA, but upon
SKIP overexpression, SKIP replaced SIRT1 on the
promoter (Figure 5F). Overall, these results suggest that
SIRT1 represses and SKIP augments RARa
transcriptional activation by competing for both RARa
binding at the protein level and RA-dependent chromatin
binding at the RAR2 promoter when they were
overexpressed.
SIRT1 and SKIP oppositely regulate RA-induced
diﬀerentiation of P19 cells
To address the biological signiﬁcance of the reciprocal
regulation of RARa transcriptional activation as
described above, we ﬁrst determined the endogenous
Figure 2. Interaction between SKIP and SIRT1 in vitro and in vivo.( A) GST pull-down assay. In vitro translated Flag-tagged SIRT1 was incubated
with GST or GST-SKIP (amino acid residues 174–373). The bound proteins were visualized by SDS–PAGE and subsequent western blotting using
anti-Flag antibody (for SIRT1). (B) Immunoprecipitation (IP) analysis. H1299 cells were co-transfected with Flag-tagged SIRT1 and GFP-tagged
SKIP, and vice versa. Lysates were subjected to IP using anti-GFP or anti-Flag antibodies. Bound protein was identiﬁed by western blotting anti-
Flag or anti-GFP antibodies. (C) Co-localization of SKIP and SIRT1. H1299 cells were transfected with GFP-SKIP and Flag-SIRT1. The cellular
location of SIRT1 was determined using Texas Red-conjugated anti-rabbit IgG. Images were visualized by ﬂuorescence microscopy. Hoechst staining
was used to locate the nucleus.
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analyzed the eﬀects of SIRT1 and SKIP on RA-induced
cellular diﬀerentiation in P19 cells. These cells represent a
murine embryonic carcinoma cell line that possesses
pluripotency, like embryonic stem cells (24), and eﬃciently
diﬀerentiates to neuron and glial cells upon RA treatment
(25). IP with anti-SKIP antibody and WB with anti-
SIRT1 antibody exhibited the endogenous interaction
between SKIP and SIRT1 (Figure 6A). Subsequent IP
assays using anti-RARa antibody indicated that RARa,
SKIP and SIRT1 form a ternary complex in the presence
of RA (Figure 6B). As shown in Figure 6C, upon RA
treatment, the P19 cells began to extrude neurite-like
structures from an embryonic body, indicative of
neuronal diﬀerentiation. However, additional treatment
with the SIRT1 activator RES prevented the P19 cells
from producing neurite-like structures. To support this
morphological change, we analyzed the mRNA expression
of nestin, a known neuronal marker (26), by RT-PCR. RA
induced the expression of nestin during diﬀerentiation, but
RA-induced nestin expression was abolished with RES
treatment (Figure 6D). Similar results were obtained
when the protein and mRNA expression of RAR and
Hox genes, a known RA target genes, was analyzed by
WB and RT-PCR, respectively (Figure 6E and F).
Overall, these ﬁndings suggest that SIRT1 interferes
with RA-induced neuronal diﬀerentiation by repressing
the expression of a neuronal marker and RAR target
genes.
To determine the reciprocal roles of SIRT1 and SKIP in
P19 cell diﬀerentiation, we used SKIP overexpression,
RES and SIRT1 siRNA. As shown in Figure 6G, SKIP
overexpression signiﬁcantly increased the formation of
neurite-like structures in the presence of RA, although
the expression vector transfection eﬃciency was <10%
in P19 cells. The number of neurite-like structures
counted per 1000 P19 cells was shown on each ﬁgure.
RES blocked SKIP-induced neuronal diﬀerentiation, and
its eﬀect was reversed by SKIP overexpression. In
addition, the depletion of SIRT1 reversed the negative
eﬀect of RES on the RA-induced neuronal diﬀerentiation,
suggesting that SIRT1 is required for RES to be negatively
functional. Consistent with the transcriptional data
shown in Figure 5, these results suggest that the reciprocal
roles of SIRT1 and SKIP in the regulation of the
transcriptional activity of RARa are responsible for
their diﬀerent roles in modulating RA-induced neuronal
diﬀerentiation of P19 cells (Figure 6H).
Figure 3. Interaction between SKIP and RARa.( A) Interaction of SKIP with nuclear receptors (NRs). Yeast two-hybrid assays were performed
with the indicated NRs in the presence of their cognate ligand. (B) Mapping of the SKIP domain responsible for the interaction with RARa in the
presence of the ligand all-trans retinoic acid (AtRA). SKIP deletions were fused to the VP AD vector and introduced into yeast L40, together with
LexA DBD-fused RARa. Fold-activity indicates the b-gal value relative to that of the VP16 AD-SKIP plus LexA DBD empty control.
(C) Immunoﬂuorescence microscopy. H1299 cells were transfected with GFP-SKIP and Flag-tagged RAR. Transfections were performed in the
absence and presence of AtRA. Hoechst staining was used to locate the nucleus.
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In this study, we demonstrated reciprocal roles of SIRT1
and SKIP in the regulation of RARa-dependent gene
transcription and RA-dependent neuronal diﬀerentiation.
We identiﬁed SKIP as a novel binding partner of SIRT1.
Extensive binding assays revealed that in addition to
binding to SIRT1, SKIP interacts with RARa through a
binding domain that overlaps that for SIRT1. We
consistently found that SIRT1 competes with SKIP for
RARa binding at the protein level and at the chromatin-
associated RAR2 promoter. This overexpression based
competition resulted in diﬀerential regulation of RARa
transactivation, with SKIP enhancing and SIRT1
repressing the transcriptional activity of RARa. Finally,
we provided evidence to suggest that the reciprocal regu-
lation of RARa-activated transcription by SIRT1 and
SKIP may account for the diﬀerential regulation of
RARa during RA-induced neuronal diﬀerentiation.
Our investigation raises questions regarding how SIRT1
represses but SKIP stimulates RARa-dependent transcrip-
tion. Recent studies have provided evidence of SIRT1
repression of transcriptional activation mediated by
other nuclear receptors such as PPAR and AR. SIRT1
represses PPARg activity by binding to its cofactors,
NCoR and SMRT, although it was uncertain whether
SIRT1 deacetylates PPARg or histones, or both, at
target genes (27). In the case of AR, SIRT1 binds
and deacetylates AR to repress AR signaling (13).
Another study on AR reported that AR antagonism
requires SIRT1 binding and deacetylation of
histone H3 locally at the AR-responsive promoter (28).
The SIRT1-mediated hypoacetylation of histone H3 has
also been implicated in the suppression of MyoD-
dependent transcription (15). In a study on the role of
SIRT1 in histone binding and histone modiﬁcation,
when SIRT1 was forced to interact with a synthetic
Gal4-responsive promoter, it deacetylated histones H3
(at lysine 9) and H4 (at lysine 16), and recruited histone
H1 to the promoter through an interaction with the
N-terminal portion of SIRT1, thereby reducing the
expression of the reporter gene (2). The involvement of
SIRT1 in other histone modiﬁcations such as methylation
is indicated by the ﬁnding that SIRT1 interacts directly
with and deacetylates histone methyltransferase
SUV39H1, speciﬁc for H3K9. The deacetylation of
SUV39H1 at its active site increases SUV39H1 activity,
thereby elevating the levels of H3K9me3 to mediate
transcriptional silencing (29). Our data revealed that
SIRT1 repression of RARa transactivation requires the
deacetylase activity of SIRT1. Transient transfection
assays also revealed that Gal4-SIRT1 could repress the
expression of a reporter gene (data not shown). It
remains to be determined whether the deacetylation
of RARa, histone or SUV39H1 is responsible for SIRT1
repression of RARa-dependent transcription. Although
the mechanism of SIRT1-mediated repression is interest-
ing, here we focused on the switching mechanism from
SIRT1 repression to SKIP activation, which provides
another level of SIRT1 regulation. We demonstrated
that overexpressed SKIP competes with and displaces
SIRT1 from a repression complex at the RARa-activated
promoter, resulting in transcriptional activation.
Figure 4. Competition between SKIP and SIRT1 for RARa binding. (A) Ternary complex among RARa, SKIP and SIRT1. H1299 cells were
transfected with Flag-tagged SKIP in the absence and presence of RA. Cell lysates were prepared and immunoprecipitated with anti-RARa antibody.
Precipitated proteins were identiﬁed on western blots using anti-Flag (for SKIP) and anti-SIRT1 antibodies. (B) Direct interaction between SIRT1
and RARa. In vitro translated RARa (in pSG5 vector) was incubated with GST or GST-SIRT1 (amino acids 114–217). The bound proteins were
visualized by SDS–PAGE and subsequent western blotting using anti-RARa antibody. (C) Competition in vivo. H1299 cells were transfected with
increasing amounts of Flag-SKIP expression vector in the presence of RA. Lysates were subjected to IP with anti-RARa antibody, followed by
western blotting with anti-SIRT1 antibody. Protein levels of endogenous RARa and overexpressed SKIP were visualized on western blots. (D) Direct
competition analysis. In vitro translated RARa was incubated with GST or GST-SIRT1 (1–217) and further reacted with increasing amounts of
in vitro translated Flag-tagged SKIP in the presence of RA. The bound proteins were visualized by SDS–PAGE and subsequent western blotting with
anti-Flag antibody.
828 Nucleic Acids Research, 2010,Vol. 38,No. 3SKIP has been described as a coactivator of Notch (30)
and nuclear receptors, including VDR (22,23), as well
as a co-repressor for Checkpoint Suppressor 1 (31),
MAGE-A1 (32) and Smad2/3 (33) in association
with the co-repressors NCoR/SMRT and/or HDAC.
Interestingly, SKIP plays a dual role in CBF1- and
nuclear receptor-mediated transcription. SKIP represses
CBF1-dependent transcription by associating with
SMRT. To activate the CBF1-repressed promoter,
NotchIC displaces SMRT from the repressor complex
and interacts with SKIP and CBF1. SKIP also regulates
nuclear receptor-mediated transcription by switching
its association with co-repressor NCoR/SMRT and
coactivator p300 (34). In this study, we provide evidence
for another role of SKIP in regulation: activated or
overexpressed SIRT1 competes with and displaces SKIP
from the activation complex at the RARa-activated
promoter, resulting in transcriptional repression.
Our study provides the ﬁrst evidence for a RAR regu-
latory pathway controlled reciprocally by SIRT1 and
SKIP, although the biological signiﬁcance of the recipro-
cal regulation remains unknown. Retinoic acid (RA) is
used to diﬀerentiate stem cells into neurons by inducing
neuron-speciﬁc genes (35,36), but its detailed mechanism
is still poorly understood. In this study, we used P19 EC
cells to delineate the molecular mechanism underlying
RA-induced neuronal diﬀerentiation and presented the
reciprocal functions of SIRT1 and SKIP. SIRT1 activa-
tion by RES repressed RA-induced diﬀerentiation,
probably through the targeted repression of the nestin
and other RA target genes, whereas SIRT1 knockdown
or SKIP overexpression stimulated RA-induced diﬀeren-
tiation. SIRT1 has been implicated in the regulation of
diﬀerentiation through adipogenesis (14,37), sper-
matogenesis (38) and neurogenesis (39,40). During the
neurogenesis of neuronal stem cells in response to envi-
ronmental redox, SIRT1 represses Mash1 transcription by
forming a complex with Hes1, but SIRT1 displacement
allows Hes1 to recruit CBP to activate Mash1 transcrip-
tion: SIRT1 drives astrocyte fate, whereas the release of
Figure 5. Reciprocal eﬀect of SKIP and SIRT1 on the transcriptional activity of RARa.( A) SKIP enhances and SIRT1 suppresses RARa
transactivation. H1299 cells were transfected with increasing amounts (0, 0.1, 0.3 and 0.5mg) of Flag-SKIP or Flag-SIRT1, in combination with
the RARa expression vector and RAR-responsive RARE-luciferase reporter. Luciferase activity was determined after normalizing to the observed
b-gal activity. All data are represented as means±SD from triplicate experiments. Fold-luciferase activity indicates the relative ratio obtained in the
presence and absence of AtRA. (B) Requirement of deacetylase activity of SIRT1 for RARa repression. H1299 cells were transfected with
combinations of SIRT1 wild type (WT), SIRT1 HY mutant (deacetylase-defective), and SKIP expression vector. Cell lysates were then subjected
to luciferase assays. (C) Depletion of SIRT1 abrogated RARa repression. H1299 cells were transfected with SIRT1 siRNA or control siRNA. Cell
lysates were subjected to luciferase assays, and the expression of SIRT1 was monitored by western blotting with anti-SIRT1 antibody. (D) SIRT1
impairs RARa transactivation induced by SKIP-SRC-1 cooperation in a deacetylase-dependent manner. H1299 cells were transfected with
combinations of SKIP, SRC-1 and SIRT1 WT or SIRT1 HY expression vectors. Cell lysates were subjected to luciferase assays. (E) Eﬀect of
SIRT1 inhibitor or activator on RARa activity. H1299 cells were transfected with SIRT1 or SKIP expression vector and treated with 240mM SIRT1
inhibitor, splitomicin (Splito) or 120mM SIRT1 activator, resveratrol (RES), for 12h. Cell lysates were subjected to luciferase assays. (F) SKIP blocks
SIRT1 binding to RA-responsive RAR2 promoter in vivo. H1299 cells were transfected with empty Flag vector or Flag-SKIP expression vector and
treated with or without 1mM AtRA for 4h. Soluble chromatin was prepared and immunoprecipitated with the indicated antibodies. The ﬁnal DNA
pellets were PCR-ampliﬁed using a primer pair that covers the RAR2 promoter region.
Nucleic AcidsResearch, 2010, Vol.38,No. 3 829SIRT1 drives neuronal fate. SIRT1 is highly expressed in
mouse embryonic stem cells (41), where it may cause the
cells to die after exposure to ROS, leaving healthy cells to
proliferate (42). Moreover, in embryonic cells, the SIRT1
inhibits the p53-mediated suppression of Nanog expres-
sion, thus allowing the cells to express Nanog and
maintain their self-renewal potential. However, the role
of SIRT1 in the RA-induced diﬀerentiation of ES cells
has not been determined. Based on the present study
using ES-like P19 cells, we propose that SIRT1 may asso-
ciate with RAR and repress RAR-activated transcription
in undiﬀerentiated P19 cells, and that SIRT1 disappears
or SKIP displace SIRT1 from RAR to enhance RAR-
mediated transcription during the neuronal diﬀerentiation
in response to RA, although the precise molecular inter-
play among RAR, SKIP and SIRT1 remains to be
determined.
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